Six CAR-T-cell therapies have been approved by the European Commission and the US FDA, and other T-cell therapies are being ...

BrightPath Bio and Cellistic have entered a process development and manufacturing agreement to progress the allogeneic CAR-T ...

Superior quality cytokines are crucial for reliable research results and the safe production of cancer cell therapies.

the 5th European CAR T-cell Meeting, Rotterdam, the Netherlands, February 9-11, 2023; the European Bone Marrow Transplant association conference, Paris, France, April 23-26, 2023; and the ISA ...

Candid Therapeutics, Inc. ("Candid"), a clinical stage biotechnology company positioned to lead the development of T cell engagers for autoimmune diseases and Ab Studio, Inc. ("Ab Studio"), a US ...

Researchers from Janssen Research & Development LLC presented preclinical data for JNJ-87801493, a first-in-class CD20 targeted CD28 costimulatory bispecific antibody (Ab), currently in early clinical ...